Google
PYPD — POLYPID (Healthcare >> Biotechnology)
PYPD FAQ
What is PYPD's ROE?
POLYPID reports a Return on Equity (ROE) of -383.02%.
What is PYPD's dividend yield?
POLYPID offers a dividend yield of 0.00%.
What is PYPD's Deepscope Quality Score?
Deepscope rates PYPD's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PYPD?
Deepscope's AI Timing Score for PYPD is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PYPD belong to?
POLYPID is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.50
Price
-0.33
(-6.83%)
Day Change
|
|
|---|
PYPD, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.50 |
| PBV / Sector |
10.64 / 4.63
|
| Earning Per Share | -1.62 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.78 M
GREAT
|
| Average 1W Daily Value |
1.11 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:07 |
| Symbol | PYPD |
| Name | POLYPID |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 19.17 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 93.38 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 18 Hasivim Street, Petah Tikva, Israel, 4959376
Phone: 972 7 4719 5700
Website: https://www.polypid.com
Employees: 69
Sector: Healthcare >> Biotechnology
Description: PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
